{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=32", "query": { "intervention": "Cohorting", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 11339, "total_pages": 1134, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T08:51:10.309Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04315298", "title": "Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1912, "start_date": "2020-03-18", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-09-23", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 62, "location_summary": "Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04315298" }, { "nct_id": "NCT01199887", "title": "Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "IW001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmuneWorks", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2010-09", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2013-07-29", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01199887" }, { "nct_id": "NCT02348216", "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "Relapsed Diffuse Large B-Cell Lymphoma", "Transformed Follicular Lymphoma (TFL)", "Primary Mediastinal B-cell Lymphoma (PMBCL)", "High Grade B-cell Lymphoma (HGBCL)" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "High-dose methylprednisolone", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 307, "start_date": "2015-04-21", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 23, "location_summary": "Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02348216" }, { "nct_id": "NCT00825084", "title": "A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease", "Huntington's Disease" ], "interventions": [ { "name": "Dimebon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 45, "start_date": "2009-02", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2011-04-26", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00825084" }, { "nct_id": "NCT03016325", "title": "Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "HNO Donor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2017-01-13", "completion_date": "2019-11-12", "has_results": true, "last_update_posted_date": "2021-01-06", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 24, "location_summary": "Tucson, Arizona • Gainesville, Florida • Tampa, Florida + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016325" }, { "nct_id": "NCT04648306", "title": "Restore EF Observational Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronary Artery Disease", "Unstable Angina", "Angina, Stable", "NSTEMI - Non-ST Segment Elevation MI" ], "interventions": [ { "name": "Prophylactic Impella support for a non-emergent PCI", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abiomed Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 406, "start_date": "2019-09-01", "completion_date": "2021-09-30", "has_results": false, "last_update_posted_date": "2021-12-14", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04648306" }, { "nct_id": "NCT07382752", "title": "Decoupling Immunotherapy Toxicity and Cancer Response", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Tumor", "Cardiovascular" ], "interventions": [], "intervention_types": [], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2026-01-09", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07382752" }, { "nct_id": "NCT00004148", "title": "Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "recombinant vaccinia-B7.1 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004148" }, { "nct_id": "NCT04085315", "title": "Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer Metastatic", "EGFR Gene Mutation" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Collin Blakely", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2019-11-12", "completion_date": "2025-10-20", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04085315" }, { "nct_id": "NCT02702115", "title": "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MPS I" ], "interventions": [ { "name": "SB-318", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sangamo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 3, "start_date": "2017-05-24", "completion_date": "2021-11-03", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-10-22T08:51:10.309Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702115" } ] }